New hope for lung cancer: experimental drug combo enters final testing phase

This study tests whether adding an experimental drug called nogapendekin alfa inbakicept (NAI) to standard chemotherapy and immunotherapy can help people with advanced non-small cell lung cancer live longer without their cancer growing. About 494 adults with stage IV lung cancer who have not had prior treatment will be randomly assigned to receive either the standard treatment alone or the standard treatment plus NAI. The main goal is to see if the combination delays cancer progression.